Novel approaches for the treatment of rheumatoid arthritis: lessons from the evaluation of synovial biomarkers in clinical trials
- 30 April 2008
- journal article
- review article
- Published by Elsevier BV in Best Practice & Research Clinical Rheumatology
- Vol. 22 (2), 311-323
- https://doi.org/10.1016/j.berh.2008.02.002
Abstract
No abstract availableKeywords
This publication has 63 references indexed in Scilit:
- Assessment of rituximab's immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker resultsAnnals Of The Rheumatic Diseases, 2007
- Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of responseAnnals Of The Rheumatic Diseases, 2007
- Tumor necrosis factor antagonist mechanisms of action: A comprehensive reviewPharmacology & Therapeutics, 2007
- Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritisAnnals Of The Rheumatic Diseases, 2007
- Phase I Evaluation of the Safety,??Pharmacokinetics and Pharmacodynamics of CP-481,715Clinical Pharmacokinetics, 2007
- Bone marrow B-lineage cells in patients with rheumatoid arthritis following rituximab therapyRheumatology, 2007
- Early effects of tumour necrosis factor blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritisAnnals Of The Rheumatic Diseases, 2004
- Evolving concepts of rheumatoid arthritisNature, 2003
- Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor α blockade in patients with rheumatoid arthritisArthritis & Rheumatism, 2000
- Modified disease activity scores that include twenty-eight-joint counts development and validation in a prospective longitudinal study of patients with rheumatoid arthritisArthritis & Rheumatism, 1995